Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom.


Journal

International journal of obesity (2005)
ISSN: 1476-5497
Titre abrégé: Int J Obes (Lond)
Pays: England
ID NLM: 101256108

Informations de publication

Date de publication:
11 2021
Historique:
received: 23 11 2020
accepted: 24 06 2021
revised: 07 06 2021
pubmed: 17 7 2021
medline: 3 11 2021
entrez: 16 7 2021
Statut: ppublish

Résumé

A detailed characterization of patients with COVID-19 living with obesity has not yet been undertaken. We aimed to describe and compare the demographics, medical conditions, and outcomes of COVID-19 patients living with obesity (PLWO) to those of patients living without obesity. We conducted a cohort study based on outpatient/inpatient care and claims data from January to June 2020 from Spain, the UK, and the US. We used six databases standardized to the OMOP common data model. We defined two non-mutually exclusive cohorts of patients diagnosed and/or hospitalized with COVID-19; patients were followed from index date to 30 days or death. We report the frequency of demographics, prior medical conditions, and 30-days outcomes (hospitalization, events, and death) by obesity status. We included 627 044 (Spain: 122 058, UK: 2336, and US: 502 650) diagnosed and 160 013 (Spain: 18 197, US: 141 816) hospitalized patients with COVID-19. The prevalence of obesity was higher among patients hospitalized (39.9%, 95%CI: 39.8-40.0) than among those diagnosed with COVID-19 (33.1%; 95%CI: 33.0-33.2). In both cohorts, PLWO were more often female. Hospitalized PLWO were younger than patients without obesity. Overall, COVID-19 PLWO were more likely to have prior medical conditions, present with cardiovascular and respiratory events during hospitalization, or require intensive services compared to COVID-19 patients without obesity. We show that PLWO differ from patients without obesity in a wide range of medical conditions and present with more severe forms of COVID-19, with higher hospitalization rates and intensive services requirements. These findings can help guiding preventive strategies of COVID-19 infection and complications and generating hypotheses for causal inference studies.

Sections du résumé

BACKGROUND
A detailed characterization of patients with COVID-19 living with obesity has not yet been undertaken. We aimed to describe and compare the demographics, medical conditions, and outcomes of COVID-19 patients living with obesity (PLWO) to those of patients living without obesity.
METHODS
We conducted a cohort study based on outpatient/inpatient care and claims data from January to June 2020 from Spain, the UK, and the US. We used six databases standardized to the OMOP common data model. We defined two non-mutually exclusive cohorts of patients diagnosed and/or hospitalized with COVID-19; patients were followed from index date to 30 days or death. We report the frequency of demographics, prior medical conditions, and 30-days outcomes (hospitalization, events, and death) by obesity status.
RESULTS
We included 627 044 (Spain: 122 058, UK: 2336, and US: 502 650) diagnosed and 160 013 (Spain: 18 197, US: 141 816) hospitalized patients with COVID-19. The prevalence of obesity was higher among patients hospitalized (39.9%, 95%CI: 39.8-40.0) than among those diagnosed with COVID-19 (33.1%; 95%CI: 33.0-33.2). In both cohorts, PLWO were more often female. Hospitalized PLWO were younger than patients without obesity. Overall, COVID-19 PLWO were more likely to have prior medical conditions, present with cardiovascular and respiratory events during hospitalization, or require intensive services compared to COVID-19 patients without obesity.
CONCLUSION
We show that PLWO differ from patients without obesity in a wide range of medical conditions and present with more severe forms of COVID-19, with higher hospitalization rates and intensive services requirements. These findings can help guiding preventive strategies of COVID-19 infection and complications and generating hypotheses for causal inference studies.

Identifiants

pubmed: 34267326
doi: 10.1038/s41366-021-00893-4
pii: 10.1038/s41366-021-00893-4
pmc: PMC8281807
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2347-2357

Informations de copyright

© 2021. The Author(s).

Références

Di Angelantonio E, Bhupathiraju SN, Wormser D, Gao P, Kaptoge S, de Gonzalez AB, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388:776–86.
doi: 10.1016/S0140-6736(16)30175-1
Hu FB. Obesity Epidemiology. New York: Oxford University Press, 2009.
Moser JAS, Galindo-Fraga A, Ortiz-Hernández AA, Gu W, Hunsberger S, Galán-Herrera JF. et al.Underweight, overweight, and obesity as independent risk factors for hospitalization in adults and children from influenza and other respiratory viruses.Influenza Other Respir Viruses.2019;13:3–9.
doi: 10.1111/irv.12618
WHO. WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020. WHO. 2020. https://www.who.int/directorgeneral/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-oncovid-19---11-march-2020 .
Louie JK, Acosta M, Samuel MC, Schechter R, Vugia DJ, Harriman K, et al. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza a (H1N1). Clin Infect Dis. 2011;52:301–12.
doi: 10.1093/cid/ciq152
GOV.UK. New obesity strategy unveiled as country urged to lose weight to beat coronavirus (COVID-19) and protect the NHS. GOV.UK. 2020. https://www.gov.uk/government/news/new-obesity-strategy-unveiled-as-country-urged-to-lose-weight-to-beat-coronavirus-covid-19-and-protect-the-nhs .
Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020;21:e13128.
doi: 10.1111/obr.13128
Griffith GJ, Morris TT, Tudball MJ, Herbert A, Mancano G, Pike L, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat Commun. 2020;11:1–12.
doi: 10.1038/s41467-020-19478-2
Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Informatics Assoc. 2015;22:553–64.
doi: 10.1093/jamia/ocu023
Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574–8.
pubmed: 26262116 pmcid: 4815923
Bolíbar B, Fina Avilés F, Morros R, Del Mar Garcia-Gil M, Hermosilla E, Ramos R, et al. Base de datos SIDIAP: La historia clínica informatizada de Atención Primaria como fuente de información para la investigación epidemiológica. Med Clin. 2012;138:617–21.
doi: 10.1016/j.medcli.2012.01.020
Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, Staa Tvan, et al. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44:827–36.
doi: 10.1093/ije/dyv098
Datta S, Posada J, Olson G, Li W, O’Reilly C, Balraj D, et al. A new paradigm for accelerating clinical data science at Stanford Medicine. arXiv:2003.10534v1 [Preprint]. 2020 [cited 2020 Aug 20]. Available from: https://arxiv.org/abs/2003.10534v1
Burn E, Tebé C, Fernandez-Bertolin S, Aragon M, Recalde M, Roel E, et al. The natural history of symptomatic COVID-19 during the first wave in Catalonia. Nat Commun. 2021;12:1–12.
doi: 10.1038/s41467-021-21100-y
Burn E, You SC, Sena AG, Kostka K, Abedtash H, Abrahão MTF, et al. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat Commun. 2020;11:5009.
doi: 10.1038/s41467-020-18849-z
Observational Health Data Sciences and Informatics. The Book of OHDSI (Independently published). 2019. https://ohdsi.github.io/TheBookOfOhdsi/ .
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052–9.
doi: 10.1001/jama.2020.6775
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399–424.
doi: 10.1080/00273171.2011.568786
Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput. 2009;38:1228–34.
doi: 10.1080/03610910902859574
World Health Organization. WHO Overweight and obesity. World Health Organization. 2020. https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/ncd-risk-factors .
Kelly SP, Lennon H, Sperrin M, Matthews C, Freedman ND, Albanes D, et al. Body mass index trajectories across adulthood and smoking in relation to prostate cancer risks: the NIH-AARP diet and health study. Int J Epidemiol. 2019;48:464–73.
doi: 10.1093/ije/dyy219
Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 states, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:458–64.
doi: 10.15585/mmwr.mm6915e3
Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.
doi: 10.1136/bmj.m1966
Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985.
doi: 10.1136/bmj.m1985
Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors associated with death in critically Ill patients with coronavirus disease 2019 in the US. JAMA Intern Med. 2020;180:1436–47.
doi: 10.1001/jamainternmed.2020.3596
Anderson MR, Geleris J, Anderson DR, Zucker J, Nobel YR, Freedberg D, et al. Body mass index and risk for intubation or death in SARS-CoV-2 infection: a retrospective cohort study. Ann Intern Med. 2020;173:782–90.
doi: 10.7326/M20-3214
Sattar N, Ho FK, Gill JM, Ghouri N, Gray SR, Celis-Morales CA, et al. BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: preliminary findings from UK biobank. Diabetes Metab Syndr Clin Res Rev. 2020;14:1149–51.
doi: 10.1016/j.dsx.2020.06.060
Tartof SY, Qian L, Hong V, Wei R, Nadjafi RF, Fischer H, et al. Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization. Ann Intern Med. 2020;173:773–81.
doi: 10.7326/M20-3742
Du Y, Lv Y, Zha W, Zhou N, Hong X. Association of body mass index (BMI) with critical COVID-19 and in-hospital mortality: a dose-response meta-analysis. Metabolism. 2021;117:154373.
doi: 10.1016/j.metabol.2020.154373
Divo MJ, Martinez CH, Mannino DM. Ageing and the epidemiology of multimorbidity. Eur Respir J. 2014;44:1055–68.
doi: 10.1183/09031936.00059814
Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc R Soc B Biol Sci. 2015;282:20143085.
doi: 10.1098/rspb.2014.3085
Muscogiuri G, Pugliese G, Laudisio D, Castellucci B, Barrea L, Savastano S, et al. The impact of obesity on immune response to infection: plausible mechanisms and outcomes. Obes Rev. 2021;22:e13216.
doi: 10.1111/obr.13216
Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis. 2020;71:896–7.
doi: 10.1093/cid/ciaa415
Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–6.
doi: 10.1038/s41586-020-2521-4
Reilev M, Kristensen KB, Pottegård A, Lund LC, Hallas J, Ernst MT, et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020;49:1468–81.
doi: 10.1093/ije/dyaa140

Auteurs

Martina Recalde (M)

Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
Universitat Autònoma de Barcelona, Bellaterra, Spain.

Elena Roel (E)

Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
Universitat Autònoma de Barcelona, Bellaterra, Spain.

Andrea Pistillo (A)

Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.

Anthony G Sena (AG)

Janssen Research & Development, Titusville, NJ, USA.
Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.

Albert Prats-Uribe (A)

Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.

Waheed-Ul-Rahman Ahmed (WU)

Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Oxford, UK.
College of Medicine and Health, University of Exeter, St Luke's Campus, Exeter, UK.

Heba Alghoul (H)

Faculty of Medicine, Islamic University of Gaza, Gaza, Palestine.

Thamir M Alshammari (TM)

College of Pharmacy, Riyadh Elm University, Riyadh, Saudi Arabia.

Osaid Alser (O)

Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Carlos Areia (C)

Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

Edward Burn (E)

Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.

Paula Casajust (P)

Real-World Evidence, Trial Form Support, Barcelona, Spain.

Dalia Dawoud (D)

Cairo University, Faculty of Pharmacy, Cairo, Egypt.

Scott L DuVall (SL)

VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, USA.
Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.

Thomas Falconer (T)

Department of Biomedical Informatics, Columbia University, New York, NY, USA.

Sergio Fernández-Bertolín (S)

Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.

Asieh Golozar (A)

Department of Epidemiology, Johns Hopkins School of Public, Baltimore, MD, USA.
Pharmacoepidemiology, Regeneron Pharmaceuticals, Tarrytown, NY, USA.

Mengchun Gong (M)

DHC Technologies co, Ltd, Beijing, China.

Lana Yin Hui Lai (LYH)

Division of Cancer Sciences, School of Medical Sciences, University of Manchester, Manchester, UK.

Jennifer C E Lane (JCE)

Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Oxford, UK.

Kristine E Lynch (KE)

VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT, USA.
Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.

Michael E Matheny (ME)

Tennessee Valley Healthcare System, Veterans Affairs Medical Center, Nashville, TN, USA.
Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.

Paras P Mehta (PP)

College of Medicine, The University of Arizona, Tucson, AZ, USA.

Daniel R Morales (DR)

Division of Population Health and Genomics, University of Dundee, Dundee, UK.

Karthik Natarjan (K)

Department of Biomedical Informatics, Columbia University, New York, NY, USA.
New York-Presbyterian Hospital, New York, NY, USA.

Fredrik Nyberg (F)

School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Jose D Posada (JD)

Department of Medicine, Stanford University, Palo Alto, CA, USA.

Christian G Reich (CG)

Real World Solutions, IQVIA, Cambridge, MA, USA.

Peter R Rijnbeek (PR)

Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.

Lisa M Schilling (LM)

Data Science to Patient Value Program, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Karishma Shah (K)

Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Oxford, UK.

Nigam H Shah (NH)

Department of Medicine, Stanford University, Palo Alto, CA, USA.

Vignesh Subbian (V)

College of Engineering, The University of Arizona, Tucson, AZ, USA.

Lin Zhang (L)

School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.

Hong Zhu (H)

Institute of Health Management, Southern Medical University, Guangzhou, China.
Nanfang Hospital, Southern Medical University, Guangzhou, China.

Patrick Ryan (P)

Janssen Research & Development, Titusville, NJ, USA.
Department of Biomedical Informatics, Columbia University, New York, NY, USA.

Daniel Prieto-Alhambra (D)

Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.
Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK.

Kristin Kostka (K)

Real World Solutions, IQVIA, Cambridge, MA, USA.
The OHDSI Center at the Roux Institute, Northeastern University, Portland, ME, USA.

Talita Duarte-Salles (T)

Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain. tduarte@idiapjgol.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH